Clinical Trial Update: A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 study of BI 1839100 for cough in idiopathic pulmonary fibrosis or progressive pulmonary fibrosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Progressive Pulmonary Fibrosis

Drugs mentioned

• BI-1839100

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Status: TERMINATED